The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis of the predictors of survival outcomes with and without allogeneic stem cell transplantation (alloSCT) after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Dr Short highlights that patients with higher-risk disease, such as those who do not achieve early measurable residual disease (MRD) negativity or have a short duration of first remission, benefit from transplant as consolidative therapy, whereas lower-risk patients do not. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
